Real-world patient eligibility for lurbinectedin/doxorubicin in small cell lung cancer

被引：0
|
作者：
Rittberg, R. [1 ]
Leung, B. [1 ]
Al-Hashami, Z. [2 ]
Ho, C. [1 ]
机构：
[1] BC Canc, Med Oncol, Vancouver, BC, Canada
[2] Sultan Qaboos Univ, Med, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151P
引用
收藏
页码：S101 / S102
页数：2
相关论文
共 50 条
  • [1] Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer
    Wasifuddin, Mustafa
    Ilerhunmwuwa, Nosakhare Paul
    Becerra, Henry
    Hakobyan, Narek
    Wasifuddin, Saad
    Al Asadi, Hayder
    Wang, Jen Chin
    JOURNAL OF CHEMOTHERAPY, 2024, 36 (07) : 587 - 592
  • [2] EMERGE 402: Real-world Characteristics and Safety of Lurbinectedin in Small-cell Lung Cancer (SCLC)
    Schreeder, D.
    Badin, F.
    Dakhil, S.
    Lammers, P.
    Patel, M.
    Slater, D.
    Migas, J.
    Naveh, N.
    Boccuti, A.
    Hanvesakul, R.
    Li, W.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E43 - E43
  • [3] Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme
    Alexander, Marliese
    Rogers, Jennifer
    Parakh, Sagun
    Mitchell, Paul
    Clay, Timothy D.
    Kao, Steven
    Hughes, Brett G. M.
    Itchins, Malinda
    Kong, Benjamin Y.
    Pavlakis, Nick
    Solomon, Benjamin J.
    John, Thomas
    INTERNAL MEDICINE JOURNAL, 2024, 54 (07) : 1087 - 1096
  • [4] Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States
    Wang, X.
    Rengarajan, B.
    Li, W.
    Prince, P.
    Paone, J.
    Rahai, N.
    Boccuti, A.
    Baratta, C.
    Lu, T.
    Cao, Y.
    Ganti, A. K.
    D'Agostino, R., Jr.
    Ben-Joseph, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S553 - S554
  • [5] Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
    Rittberg, Rebekah
    Leung, Bonnie
    Al-Hashami, Zamzam
    Ho, Cheryl
    CURRENT ONCOLOGY, 2022, 29 (12) : 9744 - 9752
  • [6] Real-World Eligibility for Clinical Trials in Extensive Stage Small Cell Lung Cancer Patients
    Dehar, N.
    Meem, M.
    Aggarwal, I.
    Hopman, W.
    Gaudreau, P. -O.
    Robinson, A.
    Fung, A. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
  • [7] EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer
    Bushunow, P.
    Dakhil, S.
    Lammers, P.
    Naveh, N.
    Boccuti, A.
    Hanvesakul, R.
    Li, W.
    Migas, J.
    Slater, D.
    Badin, F.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S145 - S146
  • [8] Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis
    Halmos, Balazs
    Lammers, Philip
    Pate, Mehul
    Shapira, Juliana
    Shunyakov, Leonid
    Slater, Dennis
    Labbe, Catherine
    Naveh, Navit
    Boccuti, Anne
    Hanvesaku, Raj
    Li, Wenyan
    Rengarajan, Badri
    Badin, Firas
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E52 - E52
  • [9] Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study
    Halmos, B.
    Lammers, P.
    Liu, G.
    Shunyakov, L.
    Madden, S.
    Kassam, S.
    Patel, M.
    Ji, Y.
    Labbe, C.
    Naveh, N.
    Ndibmun, C.
    Li, W.
    Rengarajan, B.
    Badin, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S210 - S211
  • [10] EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study
    Ganti, A. K.
    Allan, V.
    Merola, D.
    Estrin, A.
    Boccuti, A.
    Rengarajan, B.
    Baratta, C.
    Prince, P.
    Li, W.
    Cao, Y.
    D'Agostino, R. B., Jr.
    Poole, E. M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S378 - S379
12345